Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1036 - Event free survival at 24 months. A new endpoint in Diffuse large B cell lymphoma.

Date

09 Sep 2017

Session

Poster display session

Presenters

Blanca Cantos

Citation

Annals of Oncology (2017) 28 (suppl_5): v355-v371. 10.1093/annonc/mdx373

Authors

B. Cantos, J.C. Sanchez, V. Calvo de Juan, M. Mendez Garcia, C. Maximiano Alonso, D. Perez Callejo, F.F. Franco, L. Gutierrez Sanz, A. Gonzaga López, B. Nuñez, M. Provencio Pulla

Author affiliations

  • Medical Oncology, Hospital Puerta de Hierro Majadahonda, 28221 - Majadahonda/ES
More

Resources

Abstract 1036

Background

The monoclonal antibody rituximab has changed the natural history of Diffuse Large B-cell Lymphoma (DLBCL). Recent data show that patients with DLBCL achieving EFS24 (event-free survival at 24 months) after treatment with immunochemotherapy have a normal life expectancy. We have explored what happens in our patient population.

Methods

We reviewed our database of patients with lymphoma treated between 1987 and 2011. We selected DLBCL patients who had received a minimum follow up of 5 years. We included 228 patients in the analysis; 100 had received rituximab based treatment and 128 did not receive any antibody. We studied the pattern of relapse and event-free survival at 12 and 24 months from diagnosis in both populations.

Results

Our data show that the pattern of relapse in DLBCL patients has changed in the post-rituximab era. There are fewer relapses (24% versus 33%, p = 0,04) but those who relapse do so earlier: 75% of relapse occur in the first two years and late relapse (after 5 years) are rare (less than 8%) in rituximab treated patients. Patients who achieve EFS12 have a better prognosis than patients who did not achieve it (80% OS 5 years versus 15%, p 

Conclusions

Most of the patients who relapse after immunochemotherapy do so early, probably linked to a different biological behavior of the tumor. Patients who achieve EFS24 have a very good prognosis. We need to perform an accurate follow up with patients in the first 2 years after diagnosis to detect early relapses and focus on studying the molecular biology of these tumours to detect differences in relapsed patients. Follow up after 5 years from diagnosis will detect only a small account of relapses and probably will not impact on survival.

Clinical trial identification

Legal entity responsible for the study

Hospital Puerta de Hierro Majadahonda

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.